| Ebtesam Islam, MD, PHD | |
|
3601 4th St, Ms 9410, Lubbock, TX 79430-9410 | |
| (806) 743-3155 | |
| (806) 743-3143 |
| Full Name | Ebtesam Islam |
|---|---|
| Gender | Female |
| Speciality | Critical Care (intensivists) |
| Experience | 15 Years |
| Location | 3601 4th St, Lubbock, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710208913 | NPI | - | NPPES |
| 363703501 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | R0253 (Texas) | Secondary |
| 207RC0200X | Internal Medicine - Critical Care Medicine | R0253 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Medical Center | Lubbock, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Texas Tech University Health Sciences Center Lubbock | 4385549674 | 310 |
News Archive
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.
The '148 patent is a continuation of patents issued to Nanogen that cover methods and apparatus that are particularly useful for detecting varying lengths of genetic variants.
A new, lifesaving product aimed at reducing the death toll from heroin abuse - developed by a professor at the University of Kentucky College of Pharmacy - is in its final round of clinical trials and has received Fast Track designation by the Food and Drug Administration.
In a new national survey of rheumatoid arthritis (RA) patients, Health Union found a severe impact on quality of life, employment, and ability to afford treatment. The autoimmune condition attacks the body, resulting in joint inflammation, pain, stiffness, and swelling, but may also harm other organs. About 1.3 million Americans or about one percent of the global population have RA.
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.
› Verified 6 days ago
| Entity Name | Texas Tech University Health Sciences Center Lubbock |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063461358 PECOS PAC ID: 4385549674 Enrollment ID: O20110318000468 |
News Archive
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.
The '148 patent is a continuation of patents issued to Nanogen that cover methods and apparatus that are particularly useful for detecting varying lengths of genetic variants.
A new, lifesaving product aimed at reducing the death toll from heroin abuse - developed by a professor at the University of Kentucky College of Pharmacy - is in its final round of clinical trials and has received Fast Track designation by the Food and Drug Administration.
In a new national survey of rheumatoid arthritis (RA) patients, Health Union found a severe impact on quality of life, employment, and ability to afford treatment. The autoimmune condition attacks the body, resulting in joint inflammation, pain, stiffness, and swelling, but may also harm other organs. About 1.3 million Americans or about one percent of the global population have RA.
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ebtesam Islam, MD, PHD 3601 4th St, Ms 9410, Lubbock, TX 79430-9410 Ph: (806) 743-3155 | Ebtesam Islam, MD, PHD 3601 4th St, Ms 9410, Lubbock, TX 79430-9410 Ph: (806) 743-3155 |
News Archive
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer, today announced the pricing of its initial public offering of 14,300,000 shares of its common stock at $7.00 per share, before underwriting discounts and commissions. All of the shares in the offering are being sold by Merrimack.
The '148 patent is a continuation of patents issued to Nanogen that cover methods and apparatus that are particularly useful for detecting varying lengths of genetic variants.
A new, lifesaving product aimed at reducing the death toll from heroin abuse - developed by a professor at the University of Kentucky College of Pharmacy - is in its final round of clinical trials and has received Fast Track designation by the Food and Drug Administration.
In a new national survey of rheumatoid arthritis (RA) patients, Health Union found a severe impact on quality of life, employment, and ability to afford treatment. The autoimmune condition attacks the body, resulting in joint inflammation, pain, stiffness, and swelling, but may also harm other organs. About 1.3 million Americans or about one percent of the global population have RA.
Genentech, a member of the Roche Group, announced today that the U.S. Food and Drug Administration has approved an update to the Rituxan® (rituximab) label to include information on follow up treatment of adult patients with Granulomatosis with Polyangiitis and Microscopic Polyangiitis who have achieved disease control with induction treatment.
› Verified 6 days ago
Mustafa Aly, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 3615 19th St, Lubbock, TX 79410 Phone: 806-725-4130 | |
Dr. Nuvneet N/a Khandelwal, MD, MBA Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 4816 7th St, Lubbock, TX 79416 Phone: 432-230-3005 | |
Janice Stachowiak, M.D. Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 3601 4th St, Lubbock, TX 79430 Phone: 806-743-3150 Fax: 806-743-3168 | |
M Alan Sharif, M.D. Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 4802 N Loop 289, Lubbock, TX 79416 Phone: 806-788-0040 Fax: 806-788-0015 | |
Dr. Vernon Farthing, MD Critical Care Medicine Medicare: Not Enrolled in Medicare Practice Location: 3502 9th St, Ste. 210, Lubbock, TX 79415 Phone: 806-762-8461 | |
Ashref Mohamed, MD Critical Care Medicine Medicare: Accepting Medicare Assignments Practice Location: 3415 19th St, Lubbock, TX 79410 Phone: 806-725-4130 | |
Sima Lina Shahbandar, MD Critical Care Medicine Medicare: Medicare Enrolled Practice Location: 3601 4th St # Ms 9410, Lubbock, TX 79430 Phone: 806-743-6840 |